Neuropsych biotech LB Pharmaceuticals (LBRX) filed for a $100 million IPO on Friday, marking the first major new filing from a drug developer since January. Backed by a suite of VCs, LB Pharmaceuticals is initially developing its lead candidate, oral small...read more
Experienced sponsors are moving back into the SPAC market as blank check issuance has stabilized, a signal that the space has found its footing more than two years after SPAC mania ended. To some extent, they never left: Several of the largest SPAC IPOs in...read more
Helix Acquisition II, a blank check company formed by Cormorant Asset Management targeting healthcare, raised $160 million by offering 16 million shares at $10. The company offered 1 million more shares than anticipated. It originally planned to offer 10...read more
Helix Acquisition II, a blank check company formed by Cormorant Asset Management targeting healthcare, raised the proposed deal size for its upcoming IPO on Friday. The Boston, MA-based company now plans to raise $150 million by offering 15 million shares at...read more
LB Pharmaceuticals prepares to break the biotech IPO dry spell
Neuropsych biotech LB Pharmaceuticals (LBRX) filed for a $100 million IPO on Friday, marking the first major new filing from a drug developer since January. Backed by a suite of VCs, LB Pharmaceuticals is initially developing its lead candidate, oral small...read more
Back in SPACs: Experienced sponsors return to the SPAC market
Experienced sponsors are moving back into the SPAC market as blank check issuance has stabilized, a signal that the space has found its footing more than two years after SPAC mania ended. To some extent, they never left: Several of the largest SPAC IPOs in...read more
Cormorant's SPAC Helix Acquisition II prices further upsized $160 million IPO
Helix Acquisition II, a blank check company formed by Cormorant Asset Management targeting healthcare, raised $160 million by offering 16 million shares at $10. The company offered 1 million more shares than anticipated. It originally planned to offer 10...read more
Cormorant's SPAC Helix Acquisition II increases share offering by 50% ahead of $150 million IPO
Helix Acquisition II, a blank check company formed by Cormorant Asset Management targeting healthcare, raised the proposed deal size for its upcoming IPO on Friday. The Boston, MA-based company now plans to raise $150 million by offering 15 million shares at...read more